07 . 02 .2024
Press release
Galderma launches ‘NEXT’, a ground-breaking trend report that unveils the future of aesthetics
02 . 02 .2024
Press release
Galderma celebrates 25 years of excellence in biostimulation with Sculptra® at the 2024 IMCAS
25 . 01 .2024
Press release
IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position
22 . 01 .2024
Press release
Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region
17 . 01 .2024
Press release
TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously
30 . 11 .2023
Press release
Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines
21 . 11 .2023
Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories
26 . 10 .2023
Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis
13 . 10 .2023
Press release
Galderma unveils bold ambition in neuromodulation at Liquid Live event
11 . 10 .2023
Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis